BioMarin Sees Voxzogo Nearing $1.05B as Retention Holds
BioMarin Pharmaceutical's flagship therapy Voxzogo is on track to surpass $1.0 billion in revenue for 2026, driven by a 20% surge in global…
Read more: https://embers.news/article/biomarin-sees-voxzogo-nearing-105b-as-retention-holds-77476
BioMarin Pharmaceutical's flagship therapy Voxzogo is on track to surpass $1.0 billion in revenue for 2026, driven by a 20% surge in global…
Read more: https://embers.news/article/biomarin-sees-voxzogo-nearing-105b-as-retention-holds-77476
BioMarin Sees Voxzogo Nearing $1.05B as Retention Holds
BioMarin Pharmaceutical's flagship therapy Voxzogo is on track to surpass $1.0 billion in revenue for 2026, driven by a 20% surge in global patient demand, executives said at the Citi Biopharma Summit. The projected full-year 2026 revenue of $1.0 billion to $1.05 billion highlights sustained growth
embers.news
September 27, 2026 at 8:35 PM
BioMarin Sees Voxzogo Nearing $1.05B as Retention Holds
BioMarin Pharmaceutical's flagship therapy Voxzogo is on track to surpass $1.0 billion in revenue for 2026, driven by a 20% surge in global…
Read more: https://embers.news/article/biomarin-sees-voxzogo-nearing-105b-as-retention-holds-77476
BioMarin Pharmaceutical's flagship therapy Voxzogo is on track to surpass $1.0 billion in revenue for 2026, driven by a 20% surge in global…
Read more: https://embers.news/article/biomarin-sees-voxzogo-nearing-105b-as-retention-holds-77476
BioMarin Raises VOXZOGO Sales Outlook to $1 Billion Midpoint
BioMarin Pharmaceutical is expanding its rare-disease portfolio as VOXZOGO revenue growth accelerates. This performance led the c…
Read more: https://embers.news/article/biomarin-raises-voxzogo-sales-outlook-to-1-billion-midpoint-67196
BioMarin Pharmaceutical is expanding its rare-disease portfolio as VOXZOGO revenue growth accelerates. This performance led the c…
Read more: https://embers.news/article/biomarin-raises-voxzogo-sales-outlook-to-1-billion-midpoint-67196
BioMarin Raises VOXZOGO Sales Outlook to $1 Billion Midpoint
BioMarin Pharmaceutical is expanding its rare-disease portfolio as VOXZOGO revenue growth accelerates. This performance led the company to raise its full-year sales guidance for the treatment to a $1 billion midpoint. The results reflect expansion within the firm's metabolic conditions segment, whic
embers.news
September 22, 2026 at 10:31 AM
BioMarin Raises VOXZOGO Sales Outlook to $1 Billion Midpoint
BioMarin Pharmaceutical is expanding its rare-disease portfolio as VOXZOGO revenue growth accelerates. This performance led the c…
Read more: https://embers.news/article/biomarin-raises-voxzogo-sales-outlook-to-1-billion-midpoint-67196
BioMarin Pharmaceutical is expanding its rare-disease portfolio as VOXZOGO revenue growth accelerates. This performance led the c…
Read more: https://embers.news/article/biomarin-raises-voxzogo-sales-outlook-to-1-billion-midpoint-67196
🔴 #$BMRN — Clinical Milestone
Development Discontinued - VOXZOGO in Noonan Syndrome
BioMarin discontinued development of VOXZOGO (vosoritide) for children with Noonan syndrome, citing study feasibility and the current treatment landscape. The company stated the…
https://biostock.app/symbols/BMRN
Development Discontinued - VOXZOGO in Noonan Syndrome
BioMarin discontinued development of VOXZOGO (vosoritide) for children with Noonan syndrome, citing study feasibility and the current treatment landscape. The company stated the…
https://biostock.app/symbols/BMRN
September 15, 2026 at 2:23 PM
🔴 #$BMRN — Clinical Milestone
Development Discontinued - VOXZOGO in Noonan Syndrome
BioMarin discontinued development of VOXZOGO (vosoritide) for children with Noonan syndrome, citing study feasibility and the current treatment landscape. The company stated the…
https://biostock.app/symbols/BMRN
Development Discontinued - VOXZOGO in Noonan Syndrome
BioMarin discontinued development of VOXZOGO (vosoritide) for children with Noonan syndrome, citing study feasibility and the current treatment landscape. The company stated the…
https://biostock.app/symbols/BMRN
🚨 $BMRN
On September 15, 2026, BioMarin Pharmaceutical Inc. (BioMarin) announced its decision to discontinue development of VOXZOGO for children with Noonan syndrome.
On September 15, 2026, BioMarin Pharmaceutical Inc. (BioMarin) announced its decision to discontinue development of VOXZOGO for children with Noonan syndrome.
SEC Filing: BMRN
Click to view the official SEC document.
www.sec.gov
September 15, 2026 at 12:32 PM
🚨 $BMRN
On September 15, 2026, BioMarin Pharmaceutical Inc. (BioMarin) announced its decision to discontinue development of VOXZOGO for children with Noonan syndrome.
On September 15, 2026, BioMarin Pharmaceutical Inc. (BioMarin) announced its decision to discontinue development of VOXZOGO for children with Noonan syndrome.
BioMarin Welcomes Robert Plenge, M.D., Ph.D., to Its Board of Directors as New Chief Research Officer#United_States#San_Rafael#Rare_Diseases#BioMarin#Dr._Plenge
BioMarin Welcomes Robert Plenge, M.D., Ph.D., to Its Board of Directors as New Chief Research Officer
BioMarin Pharmaceutical has appointed Dr. Robert Plenge to its Board of Directors, bringing extensive research experience to the role.
third-news.com
September 14, 2026 at 2:59 PM
BioMarin Welcomes Robert Plenge, M.D., Ph.D., to Its Board of Directors as New Chief Research Officer#United_States#San_Rafael#Rare_Diseases#BioMarin#Dr._Plenge
BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer) (cik: 0001048477) filed an 8-K update with an Item 5.02. See the filing at https://www.sec.gov/Archives/edgar/data/1048477/000162828026061717/0001628280-26-061717-index.htm
September 14, 2026 at 1:41 PM
BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer) (cik: 0001048477) filed an 8-K update with an Item 5.02. See the filing at https://www.sec.gov/Archives/edgar/data/1048477/000162828026061717/0001628280-26-061717-index.htm
🚨 $BMRN
On September 10, 2026, the Board of Directors (the Board) of BioMarin Pharmaceutical Inc. (the Company) increased the size of the Board from ten to eleven members and appointed Robert Plenge, M.D., Ph.D., to the Board, to be effective September 10, 2026 (the Appointment Date). Dr. Plenge ...
On September 10, 2026, the Board of Directors (the Board) of BioMarin Pharmaceutical Inc. (the Company) increased the size of the Board from ten to eleven members and appointed Robert Plenge, M.D., Ph.D., to the Board, to be effective September 10, 2026 (the Appointment Date). Dr. Plenge ...
SEC Filing: BMRN
Click to view the official SEC document.
www.sec.gov
September 14, 2026 at 1:27 PM
🚨 $BMRN
On September 10, 2026, the Board of Directors (the Board) of BioMarin Pharmaceutical Inc. (the Company) increased the size of the Board from ten to eleven members and appointed Robert Plenge, M.D., Ph.D., to the Board, to be effective September 10, 2026 (the Appointment Date). Dr. Plenge ...
On September 10, 2026, the Board of Directors (the Board) of BioMarin Pharmaceutical Inc. (the Company) increased the size of the Board from ten to eleven members and appointed Robert Plenge, M.D., Ph.D., to the Board, to be effective September 10, 2026 (the Appointment Date). Dr. Plenge ...
BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis
BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis - BeyondLink
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)'s stock rose 5% on August 31 after the company announced that it has entered into binding agreements with Ascendis
beyondlink.live
September 14, 2026 at 3:24 AM
BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis
軟骨無形成低身長症へのVOXZOGO第3相結果をBioMarinが発表──NEJM Evidence掲載、FDA申請の根拠データを整理
stellanews.life/technology/1... #CANOPY-HCH-3 #vosoritide
stellanews.life/technology/1... #CANOPY-HCH-3 #vosoritide
軟骨無形成低身長症へのVOXZOGO第3相結果をBioMarinが発表──NEJM Evidence掲載、FDA申請の根拠データを整理
BioMarin Pharmaceuticalは2026年9月9日、軟骨無形成低身長症（hypochondroplasia）を対象とした第3相CANOPY-HCH-3試験でVOXZOGO（vosoritide）が主要評価項目を達成したと発表した。成長速度や身長など複数指標の結果と安全性、FDA申請の状況を整理する。
stellanews.life
September 11, 2026 at 11:10 PM
軟骨無形成低身長症へのVOXZOGO第3相結果をBioMarinが発表──NEJM Evidence掲載、FDA申請の根拠データを整理
stellanews.life/technology/1... #CANOPY-HCH-3 #vosoritide
stellanews.life/technology/1... #CANOPY-HCH-3 #vosoritide
【低軟骨形成症、年間成長がプラセボより2.33cm多い】
BioMarinのボソリチド第3相。52週の年間成長速度の差は2.33cm、身長Zスコア差は0.39SD。適応拡大の申請をFDAへ出した。
BioMarinのボソリチド第3相。52週の年間成長速度の差は2.33cm、身長Zスコア差は0.39SD。適応拡大の申請をFDAへ出した。
September 11, 2026 at 11:10 PM
【低軟骨形成症、年間成長がプラセボより2.33cm多い】
BioMarinのボソリチド第3相。52週の年間成長速度の差は2.33cm、身長Zスコア差は0.39SD。適応拡大の申請をFDAへ出した。
BioMarinのボソリチド第3相。52週の年間成長速度の差は2.33cm、身長Zスコア差は0.39SD。適応拡大の申請をFDAへ出した。
Ascendis and BioMarin have settled their YUVIWEL dispute. Ascendis will pay BioMarin royalties up to 20% on navepegritide net sales through May 2030, ending all litigation between the companies.
Ascendis and BioMarin settle YUVIWEL dispute with royalty deal
Ascendis Pharma will pay BioMarin royalties of up to 20% on navepegritide net sales through May 2030 to resolve all litigation between the two companies.
biotech.disruptsmedia.com
September 11, 2026 at 4:00 PM
Ascendis and BioMarin have settled their YUVIWEL dispute. Ascendis will pay BioMarin royalties up to 20% on navepegritide net sales through May 2030, ending all litigation between the companies.
BioMarin Presents Encouraging Phase 3 Results for VOXZOGO in Children with Hypochondroplasia#USA#San_Rafael#BioMarin#VOXZOGO#Hypochondroplasia
BioMarin Presents Encouraging Phase 3 Results for VOXZOGO in Children with Hypochondroplasia
BioMarin has reported significant improvements in growth measures for VOXZOGO, aimed at treating hypochondroplasia in children, during Phase 3 trials.
third-news.com
September 9, 2026 at 1:43 PM
BioMarin Presents Encouraging Phase 3 Results for VOXZOGO in Children with Hypochondroplasia#USA#San_Rafael#BioMarin#VOXZOGO#Hypochondroplasia
Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute
arc-codex.com
September 3, 2026 at 11:48 AM
Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute
$BMRN — Other Company Update
BioMarin Pharmaceutical Inc. completed its acquisition of Alesta Therapeutics B.V.
🧵 continued ↓
BioMarin Pharmaceutical Inc. completed its acquisition of Alesta Therapeutics B.V.
🧵 continued ↓
September 1, 2026 at 8:16 PM
$BMRN — Other Company Update
BioMarin Pharmaceutical Inc. completed its acquisition of Alesta Therapeutics B.V.
🧵 continued ↓
BioMarin Pharmaceutical Inc. completed its acquisition of Alesta Therapeutics B.V.
🧵 continued ↓
📢 Biomarin Pharmaceutical is #hiring a Brand Lead, Skeletal Conditions Germany!
🌎 Germany
🔗 http://jbs.ink/hSbgwtYAouNL
#jobalert #jobsearch #familyofficejobs #marketing
🌎 Germany
🔗 http://jbs.ink/hSbgwtYAouNL
#jobalert #jobsearch #familyofficejobs #marketing
September 1, 2026 at 7:37 PM
📢 Biomarin Pharmaceutical is #hiring a Brand Lead, Skeletal Conditions Germany!
🌎 Germany
🔗 http://jbs.ink/hSbgwtYAouNL
#jobalert #jobsearch #familyofficejobs #marketing
🌎 Germany
🔗 http://jbs.ink/hSbgwtYAouNL
#jobalert #jobsearch #familyofficejobs #marketing
BioMarin Pharmaceutical $BMRN: Piper Sandler raised its price target from $88.00 to $90.00 and maintained its Overweight rating.
https://fundspec.ai/s/BMRN/analysts
Read the social chatter around a ticker before the move.
https://fundspec.ai/s/BMRN/analysts
Read the social chatter around a ticker before the move.
September 1, 2026 at 5:45 PM
BioMarin Pharmaceutical $BMRN: Piper Sandler raised its price target from $88.00 to $90.00 and maintained its Overweight rating.
https://fundspec.ai/s/BMRN/analysts
Read the social chatter around a ticker before the move.
https://fundspec.ai/s/BMRN/analysts
Read the social chatter around a ticker before the move.
BioMarin Finalizes Acquisition of Alesta Therapeutics to Enhance Rare Disease Portfolio#USA#San_Rafael#BioMarin#Alesta_Therapeutics#ALE1
BioMarin Finalizes Acquisition of Alesta Therapeutics to Enhance Rare Disease Portfolio
BioMarin Pharmaceutical has successfully completed the acquisition of Alesta Therapeutics, aiming to strengthen its position in the rare disease sector with ALE1.
third-news.com
September 1, 2026 at 1:27 PM
BioMarin Finalizes Acquisition of Alesta Therapeutics to Enhance Rare Disease Portfolio#USA#San_Rafael#BioMarin#Alesta_Therapeutics#ALE1
🚨 $BMRN
As previously reported in the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on August 18, 2026, BioMarin Pharmaceutical Inc., a Delaware corporation , entered into a Share Purchase Agreement with (i) Alesta Therapeutics B.V., a Dutch private limited lia...
As previously reported in the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on August 18, 2026, BioMarin Pharmaceutical Inc., a Delaware corporation , entered into a Share Purchase Agreement with (i) Alesta Therapeutics B.V., a Dutch private limited lia...
SEC Filing: BMRN
Click to view the official SEC document.
www.sec.gov
September 1, 2026 at 1:24 PM
🚨 $BMRN
As previously reported in the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on August 18, 2026, BioMarin Pharmaceutical Inc., a Delaware corporation , entered into a Share Purchase Agreement with (i) Alesta Therapeutics B.V., a Dutch private limited lia...
As previously reported in the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on August 18, 2026, BioMarin Pharmaceutical Inc., a Delaware corporation , entered into a Share Purchase Agreement with (i) Alesta Therapeutics B.V., a Dutch private limited lia...